Breaking News Instant updates and real-time market news.

ALPN

Alpine Immune Sciences

$5.27

-0.34 (-6.06%)

, GILD

Gilead

$66.91

-0.24 (-0.36%)

13:30
05/24/19
05/24
13:30
05/24/19
13:30

Alpine Immune Sciences reports notice of termination of license pact with Kite

In a regulatory filing earlier, Alpine Immune Sciences (ALPN) disclosed that on May 20, Kite Pharma, a Gilead (GILD) company, provided the company notice of termination of the license and research agreement, by and between a wholly-owned subsidiary of the company and Kite, dated as of October 26, 2015, as amended. Kite terminated the agreement following the expiration of the research term, as defined in the agreement. Upon termination, the confidentiality and indemnity obligations of the parties will survive and the licenses granted to Kite under the agreement will terminate. Pursuant to the terms of the agreement, the termination will be effective on June 20, thirty days after the effectiveness of Kite's notice, Alpine stated.

ALPN

Alpine Immune Sciences

$5.27

-0.34 (-6.06%)

GILD

Gilead

$66.91

-0.24 (-0.36%)

  • 31

    May

  • 13

    Jun

ALPN Alpine Immune Sciences
$5.27

-0.34 (-6.06%)

11/11/18
PIPR
11/11/18
NO CHANGE
Target $12
PIPR
Overweight
Piper Jaffray bullish on Alpine after 'robust' ALPN-202 preclinical activity
Piper Jaffray analyst Edward Tenthoff notes that Alpine Immune Sciences presented two posters at SITC for immuno-oncology variable Immunoglobulin Domain candidates. The analyst points out that new preclinical data on ALPN-202, which co-engages PD-L1 and CTLA-4 to selectively stimulates CD28 on T-cells, demonstrated "robust" anti-tumor activity in vivo compared to single agent anti-PD-1 durvalumab. He believes SITC data indicated vIgDs unique co-engagement at the synpase generates superior anti-tumor activity, and says Alpine will file an IND on lead autoimmune vIgD ALPN-101 by year-end 2018 and could prove superior to Orencia with preclinical data at ASH. Tenthoff reiterates an Overweight rating and $12 price target on the shares.
12/02/18
PIPR
12/02/18
NO CHANGE
Target $12
PIPR
Overweight
Alpine Immune Sciences' ALPN-101 active in GvHD, CTA by YE18, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff notes that Alpine (ALPN) presented two posters at ASH on proprietary variable Immunoglobulin Domain technology. In vivo data at ASH showed single doses enhanced survival in GvHD models compared to Bristol Myer's (BMY) Nujolix, he notes, adding that a CTA for ALPN-101 by YE18 should enable healthy volunteer data and lead to a Phase II GvHD start next year. The analyst also points out that Alpine presented novel Transmembrane ImmuneModulatory Proteins that can be engineered into T cells to enhance response in immunosuppressive environments. Importantly these strategies differ from TIP technology partnered to Kite (GILD) and offer further partnering opportunity, Tenthoff contends. He reiterates an Overweight rating and $12 price target on Alpine's shares.
01/22/19
PIPR
01/22/19
NO CHANGE
Target $11
PIPR
Overweight
Alpine Immune Sciences target lowered to $11 placement dilution at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff lowered his price target for Alpine Immune Sciences to $11 from $12 to reflect dilition from the company's recent private placement. Alpine recently issued 4.7 million units at $5.37 comprised of one share and 0.39 warrants with a $12.74 strike price raising gross proceeds of $25.3M, Tenthoff tells investors in a research note. The analyst estimates Alpine now holds pro forma cash of $86M to advance its pipeline of proprietary variant Ig domains as novel immunotherapies. He reiterates an Overweight rating on the shares.
05/15/19
PIPR
05/15/19
NO CHANGE
Target $11
PIPR
Overweight
Piper sees broad partnership potential for Alpine after Adaptimmune deal
After Alpine Immune Sciences (ALPN) announced a partnership with Adaptimmune (ADAP) to incorporate its novel Transmembrane and Secreted Immunomodulatory Proteins, or TIPs and SIPs, into CAR-T cells, Piper Jaffray analyst Edward Tenthoff said he sees Alpine having broad potential to partner its TIPs and SIPs for next generation cellular therapies. The analyst, who noted that Alpine is also advancing a platform of novel variant Ig domains, or "vIgDs," to augment T-cell activation, keeps an Overweight rating and $11 price target on Alpine shares.
GILD Gilead
$66.91

-0.24 (-0.36%)

05/13/19
JEFF
05/13/19
NO CHANGE
Target $95
JEFF
Buy
Gilead shares reflect 'undue bearish outlook,' says Jefferies
Gilead Sciences (GILD) is trading at a 10 times price-to-earnings multiple, which reflects an "undue bearish outlook," Jefferies analyst Michael Yee tells investors in a research note. He thinks the company's base HIV business growing to 2025 and then eroding is worth $60-$65 per share, and the rest of business -- HCV, filgotinib, Yescarta -- is worth $15-$20 per share. This implies the stock should be at $80-$85, says Yee. A bear case on the HIV business is $35-$40 per share, which assumes a full cliff post 2025 or GlaxoSmithKline (GSK) taking "massive" share with doublets and long-acting, adds the analyst. Yee keeps a Buy rating on Gilead with a $95 price target.
05/20/19
FBCO
05/20/19
INITIATION
Target $70
FBCO
Neutral
Gilead initiated with a Neutral at Credit Suisse
Credit Suisse analyst Evan Seigerman started Gilead Sciences with a Neutral rating and $70 price target. The does not see "outsized growth" in the company's base HIV business that would drive significant upside to earnings projections. He admits, however, that a new strategic vision or acquisition could lead to multiplier expansion.
05/22/19
SBSH
05/22/19
UPGRADE
SBSH
Buy
Gilead upgraded to Buy from Neutral at Citi
05/22/19
05/22/19
UPGRADE

Citi assumes coverage of large-cap biotech, upgrades Amgen and Gilead
Citi analyst Mohit Bansal assumed coverage of large-cap biotech stocks, assuming coverage with five Buy ratings -- Amgen (AMGN), Alexion Pharmaceuticals (ALXN), Vertex Pharmaceuticals (VRTX), Gilead Sciences (GILD), and BioMarin Pharmaceutical (BMRN) -- and two Neutral ratings -- Biogen (BIIB) and Regeneron Pharmaceuticals (REGN). Both Amgen and Gilead were upgraded to Buy from Neutral as part of the assumption of coverage. The analyst said he is "more optimistic" on the sector as a whole as he sees many biotechs going "back to basics" by investing in their internal pipelines and filling their pipelines with early stage assets. He suggests looking at large caps again, as many are returning to stability and growth. Bansal does not favor large M&A, suggesting discipline due to "realizing value with big M&As."

TODAY'S FREE FLY STORIES

NTRS

Northern Trust

$85.86

-1.3 (-1.49%)

06:36
06/18/19
06/18
06:36
06/18/19
06:36
Downgrade
Northern Trust rating change  »

Northern Trust downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

BK

BNY Mellon

$43.95

-0.54 (-1.21%)

06:36
06/18/19
06/18
06:36
06/18/19
06:36
Downgrade
BNY Mellon rating change  »

BNY Mellon downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 06

    Aug

PSN

Parsons

$31.33

-0.39 (-1.23%)

06:36
06/18/19
06/18
06:36
06/18/19
06:36
Earnings
Parsons reports Q1 adj. EPS 57c, consensus 13c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

SCHW

Charles Schwab

$40.60

-0.41 (-1.00%)

06:36
06/18/19
06/18
06:36
06/18/19
06:36
Downgrade
Charles Schwab rating change  »

Charles Schwab downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

ALXN

Alexion

$120.11

2.17 (1.84%)

06:35
06/18/19
06/18
06:35
06/18/19
06:35
Hot Stocks
Alexion announces approval of Ultomiris in Japan »

Alexion Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

GCP

GCP Applied Technologies

$26.36

-0.3 (-1.13%)

06:34
06/18/19
06/18
06:34
06/18/19
06:34
Hot Stocks
GCP Applied Technologies to pursue standalone strategic plan »

The Board of Directors of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NRZ

New Residential

$15.58

0.12 (0.78%)

06:33
06/18/19
06/18
06:33
06/18/19
06:33
Hot Stocks
New Residential enters into APA to acquire forward assets of Ditech Financial »

New Residential…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MRK

Merck

$83.30

0.52 (0.63%)

, AZN

AstraZeneca

$39.98

0.3 (0.76%)

06:32
06/18/19
06/18
06:32
06/18/19
06:32
Hot Stocks
Merck, AstraZeneca announce LYNPARZA approved in EU »

AstraZeneca (AZN) and…

MRK

Merck

$83.30

0.52 (0.63%)

AZN

AstraZeneca

$39.98

0.3 (0.76%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

  • 20

    Jun

  • 20

    Jun

  • 24

    Jun

  • 16

    Jul

  • 30

    Jul

  • 06

    Aug

  • 16

    Sep

  • 20

    Sep

TTMI

TTM Technologies

$9.46

0.05 (0.53%)

06:32
06/18/19
06/18
06:32
06/18/19
06:32
Recommendations
TTM Technologies analyst commentary  »

TTM Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BCE

BCE

$44.29

-0.345 (-0.77%)

06:27
06/18/19
06/18
06:27
06/18/19
06:27
Upgrade
BCE rating change  »

BCE upgraded to Buy from…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

JPM

JPMorgan

$109.20

-0.64 (-0.58%)

, GS

Goldman Sachs

$190.74

-0.97 (-0.51%)

06:25
06/18/19
06/18
06:25
06/18/19
06:25
Periodicals
JPMorgan working on secretive digital banking project, TechCrunch reports »

JPMorgan (JPM) is working…

JPM

JPMorgan

$109.20

-0.64 (-0.58%)

GS

Goldman Sachs

$190.74

-0.97 (-0.51%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

  • 09

    Jul

  • 16

    Jul

  • 16

    Jul

  • 06

    Aug

ARRY

Array BioPharma

$46.42

16.83 (56.88%)

06:22
06/18/19
06/18
06:22
06/18/19
06:22
Downgrade
Array BioPharma rating change  »

Array BioPharma…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSLA

Tesla

$225.00

10.19 (4.74%)

06:21
06/18/19
06/18
06:21
06/18/19
06:21
Periodicals
Musk deletes tweet attacking Tesla co-founder Eberhard, Business Insider reports »

Tesla CEO Elon Musk…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DIS

Disney

$140.95

-0.69 (-0.49%)

06:19
06/18/19
06/18
06:19
06/18/19
06:19
Recommendations
Disney analyst commentary  »

Media survey shows strong…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

RTN

Raytheon

$179.77

2.39 (1.35%)

06:18
06/18/19
06/18
06:18
06/18/19
06:18
Hot Stocks
Raytheon, Black Sage partner on drone detection »

Raytheon and Black Sage…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TGI

Triumph Group

$18.69

-1.37 (-6.83%)

06:17
06/18/19
06/18
06:17
06/18/19
06:17
Hot Stocks
Triumph Group unit to provide engineering services for Mitsubishi Aircraft »

Triumph Group announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

AZN

AstraZeneca

$39.98

0.3 (0.76%)

, MRK

Merck

$83.30

0.52 (0.63%)

06:16
06/18/19
06/18
06:16
06/18/19
06:16
Hot Stocks
AstraZeneca's Lynparza approved as 1st line ovarian cancer maintenance treatment »

AstraZeneca (AZN) and…

AZN

AstraZeneca

$39.98

0.3 (0.76%)

MRK

Merck

$83.30

0.52 (0.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

  • 20

    Jun

  • 20

    Jun

  • 24

    Jun

  • 16

    Jul

  • 30

    Jul

  • 06

    Aug

  • 16

    Sep

  • 20

    Sep

TGI

Triumph Group

$18.69

-1.37 (-6.83%)

06:15
06/18/19
06/18
06:15
06/18/19
06:15
Hot Stocks
Triumph Group, Air France announce strategic alliance »

Triumph Group and Air…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

UTX

United Technologies

$124.14

-1.16 (-0.93%)

06:14
06/18/19
06/18
06:14
06/18/19
06:14
Hot Stocks
United Technologies' Collins Aerospace secures more than $1.5B in agreements »

Collins Aerospace…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVDA

Nvidia

$144.98

0.39 (0.27%)

, VOLVY

Volvo

$0.00

(0.00%)

06:12
06/18/19
06/18
06:12
06/18/19
06:12
Hot Stocks
Nvidia, Volvo partner to develop AI platform for autonomous trucks »

The Volvo Group (VOLVY)…

NVDA

Nvidia

$144.98

0.39 (0.27%)

VOLVY

Volvo

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jul

  • 15

    Aug

AL

Air Lease

$38.66

-0.185 (-0.48%)

, EADSY

Airbus

$0.00

(0.00%)

06:12
06/18/19
06/18
06:12
06/18/19
06:12
Hot Stocks
Air Lease announces lease placement of 6 new Airbus A330-900neos with Virgin »

Air Lease (AL) announced…

AL

Air Lease

$38.66

-0.185 (-0.48%)

EADSY

Airbus

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

WHD

Cactus

$30.63

-0.505 (-1.62%)

06:10
06/18/19
06/18
06:10
06/18/19
06:10
Recommendations
Cactus analyst commentary  »

Cactus price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VWAGY

Volkswagen

$0.00

(0.00%)

06:10
06/18/19
06/18
06:10
06/18/19
06:10
Hot Stocks
Volkswagen aims to boost in-house software development to 60% by 2025 »

Volkswagen AG said in a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AL

Air Lease

$38.66

-0.185 (-0.48%)

, EADSY

Airbus

$0.00

(0.00%)

06:10
06/18/19
06/18
06:10
06/18/19
06:10
Hot Stocks
Air Lease announces lease placement of 3 new Airbus A321-200neo with Sky Airline »

Air Lease (AL) announced…

AL

Air Lease

$38.66

-0.185 (-0.48%)

EADSY

Airbus

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

SPR

Spirit AeroSystems

$79.73

1.16 (1.48%)

, EADSY

Airbus

$0.00

(0.00%)

06:09
06/18/19
06/18
06:09
06/18/19
06:09
Hot Stocks
Spirit AeroSystems announces role across four projects on Airbus program »

Spirit AeroSystems (SPR)…

SPR

Spirit AeroSystems

$79.73

1.16 (1.48%)

EADSY

Airbus

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.